BOSTON and MONTREAL, March 5,
2024 /CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) or
"enGene" or the "Company"), a clinical-stage genetic medicines
company whose non-viral lead program EG-70 is in a pivotal study
for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC),
today announced that Jason Hanson,
Chief Executive Officer, will present at the Leerink Partners
Global Biopharma Conference in Miami,
FL on March 13, 2024, at
8:40 a.m. ET.
A live webcast of the presentation can be accessed under the
Investors section of the enGene website at
www.engene.com/presentations and will be archived there for 90
days.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming
genetic medicines through the delivery of therapeutics to mucosal
tissues and other organs, with the goal of creating new ways to
address diseases with high clinical needs. enGene's lead program is
EG-70 for patients with non-muscle invasive bladder cancer (NMIBC)
with carcinoma in situ (Cis) who are unresponsive or naïve to
treatment with Bacillus Calmette-Guérin (BCG) – a disease with a
high clinical burden. EG-70 is being evaluated in an ongoing Phase
2 pivotal study. EG-70 was developed using enGene's proprietary
Dually Derivatized Oligochitosan (DDX) platform, which enables
penetration of mucosal tissues and delivery of a wide range of
sizes and types of cargo, including DNA and various forms of RNA.
enGene became a publicly traded company effective November 1, 2023, upon the completion of a
business combination with Forbion European Acquisition Corporation,
a special purpose acquisition company. For more information, visit
enGene.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/engene-to-present-at-the-leerink-partners-global-biopharma-conference-302079234.html
SOURCE enGene Inc.